Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Jan Cerny"'
Publikováno v:
Cancer Management and Research
Platelet-derived growth factor-beta (PDGFRB) gene maps for the receptor tyrosine kinase PDGRFβ. PDGFRB gene fusions have been implicated in multiple myeloid and lymphoid neoplasms and have shown exquisite sensitivity to tyrosine kinase inhibitors. W
Autor:
Siddhartha Ganguly, Andrew Daly, Tracey A. O'Brien, Melhem Solh, Steven Z. Pavletic, Rammurti T. Kamble, Leslie Lehmann, Tao Wang, Takanori Teshima, Amer Beitinjaneh, Miguel Pérez, Mahmoud Aljurf, Mukta Arora, John L. Wagner, Medhat Askar, Marjolein van der Poel, Madan Jagasia, Rabi Hanna, Alvaro Urbano-Ispizua, Ravi Vij, Armin Rashidi, Taiga Nishihori, Catherine J. Lee, A. Samer Al-Homsi, Vijaya Raj Bhatt, Michael T. Hemmer, Roger Strair, Hannah Choe, Joseph Pidala, Jeffery J. Auletta, Hisham Abdel-Azim, Vaibhav Agrawal, Shahinaz M. Gadalla, Stefan O. Ciurea, S Spellman, Margaret L. MacMillan, Rodrigo Martino, Jean-Yves Cahn, Mitchell S. Cairo, Basem M. William, Rizwan Romee, Jean A. Yared, Navneet S. Majhail, Annie Im, Usama Gergis, Mohamed A. Kharfan-Dabaja, Richard F. Olsson, Sagar S. Patel, Baldeep Wirk, Peiman Hematti, Michael Byrne, Asad Bashey, Hemant S. Murthy, Betty K. Hamilton, Muna Qayed, Pooja Khandelwal, Robert Peter Gale, Saurabh Chhabra, Gerhard C. Hildebrandt, Jan Cerny, Sachiko Seo, Roger H. Herzig, Nosha Farhadfar, Deepesh Lad, Hélène Schoemans, Akshay Sharma, Tim Prestidge, Lazaros J. Lekakis, Daniel J. Weisdorf, Paul Castillo, Miguel-Angel Perales
Publikováno v:
Biol Blood Marrow Transplant
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Biology of Blood and Marrow Transplantation, 26(8), 1459-1468. Elsevier Science
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Biology of Blood and Marrow Transplantation, 26(8), 1459-1468. Elsevier Science
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVH
Autor:
Sunita Nathan, Richard F. Olsson, Mohamed A. Kharfan-Dabaja, Nelli Bejanyan, Nilanjan Ghosh, Sachiko Seo, Umar Farooq, Kwang Woo Ahn, Saurabh Chhabra, Basem M. William, Mehdi Hamadani, Mitchell S. Cairo, Matthew Mei, Timothy S. Fenske, Parastoo B. Dahi, Carlos Litovich, Manoj Khanal, Marjolein van der Poel, Amir Steinberg, Jennifer A. Kanakry, Jan Cerny, Sairah Ahmed, Anna Sureda, Alberto Mussetti
Publikováno v:
British Journal of Haematology, 190(4), 573-582. Wiley
Reduced-intensity conditioning (RIC) allogeneic haematopoietic cell transplantation (allo-HCT) is a curative option for select relapsed/refractory Hodgkin lymphoma (HL) patients; however, there are sparse data to support superiority of any particular
Autor:
Michael Byrne, Jane L. Liesveld, Richard F. Olsson, Sagar S. Patel, Hongtao Liu, Eric Wong, Brenda M. Sandmaier, Bipin N. Savani, Hannah Choe, Partow Kebriaei, Gulrayz Ahmed, Tania Jain, Moussab Damlaj, Rebecca L. Olin, Mehdi Hamadani, Uday R. Popat, Neil Palmisiano, Rajneesh Nath, Mei-Jie Zhang, Mark R. Litzow, Attaphol Pawarode, Mark P. Hertzberg, Taiga Nishihori, Arnon Nagler, Jean A. Yared, Mitchell S. Cairo, Ioannis Politikos, Michael R. Grunwald, Hisham Abdel-Azim, Usama Gergis, David A. Rizzieri, Baldeep Wirk, Ashish Bajel, Rammurti T. Kamble, Hemant S. Murthy, Jean-Yves Cahn, Corey Cutler, Mahmoud Aljurf, A. Samer Al-Homsi, Geoffrey L. Uy, Miguel-Angel Perales, Muhammad Waqas Khan, Miguel Angel Diaz, Minocher Battiwalla, Mohamed A. Kharfan-Dabaja, Nosha Farhadfar, Natasha Kekre, Vaibhav Agrawal, Hillard M. Lazarus, Jan Cerny, Rodrigo Martino, Nandita Khera, Youjin Wang, Asmita Mishra, Nasheed Hossain, Luis Isola, Leo F. Verdonck, Nirav N. Shah, Vijaya Raj Bhatt, Zachariah DeFilipp, Daniel J. Weisdorf, Vikram Mathews, Edward A. Copelan, Aaron T. Gerds, C. Esar O. Freytes, David Valc A. Arcel, Shahrukh K. Hashmi, Mrinal M. Patnaik, Sunita Nathan, Sachiko Seo, Marcos de Lima, Qaiser Bashir, David I. Marks, Zheng Zhou, Yoshihiro Inamoto, Ryotaro Nakamura, Hai-Lin Wang, Edmund K. Waller, James M. Foran, Gerhard C. Hildebrandt, Amer Assal, Zartash Gul, Hassan B. Alkhateeb, Ulrike Bacher, Wael Saber
Publikováno v:
Blood Advances
There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center
Autor:
Witold B. Rybka, Mark R. Litzow, Hillard M. Lazarus, Jan Cerny, Xin Victoria Wang, Jacob M. Rowe, Martin S. Tallman, Stephen A. Strickland
Publikováno v:
Leukemia & Lymphoma. 61:2191-2199
High-dose cytarabine (HiDAC) consolidation for acute myeloid leukemia (AML) induces transient profound myelosuppression and potential morbidity/mortality. PrE0901 was a phase I multi-center trial evaluating the safety/toxicity of eltrombopag in AML p
Autor:
Narendranath Epperla, Ang Li, Brent Logan, Caitrin Fretham, Saurabh Chhabra, Mahmoud Aljurf, Lynette Chee, Edward Copelan, César O. Freytes, Peiman Hematti, Hillard M. Lazarus, Mark Litzow, Taiga Nishihori, Richard F. Olsson, Tim Prestidge, Wael Saber, Baldeep Wirk, Jean A. Yared, Alison Loren, Marcelo Pasquini, Allistair A. Abraham, Vaibhav Agrawal, Medhat Askar, Pere Barba, Alice Bertaina, Jean‐Yves Cahn, Jan Cerny, Hannah K. Choe, Miguel Angel Diaz, Christopher Dvorak, Nosha Farhadfar, Shahinaz M. Gadalla, Usama Gergis, Siddhartha Ganguly, Shahrukh Hashmi, Kimberly A. Kasow, Sunita Nathan, Roomi Nusrat, Sachiko Seo, Niketa C. Shah
Publikováno v:
British Journal of Haematology. 189:1171-1181
Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of allogeneic transplantation (allo-HCT). The incidence and risk factors associated with TA-TMA are not well known. A retrospective analysis from the Center for International
Autor:
Ulrike Bacher, Wael Saber, Uday R. Popat, Amer Beitinjaneh, Richard Gopez Ancheta, Shahinaz M. Gadalla, Jean-Yves Cahn, Ying Liu, Michael R. Grunwald, Hillard M. Lazarus, Jeff Szer, Naeem Chaudhri, Hisham Abdel-Azim, Nasheed Hossain, Richard F. Olsson, Gerhard C. Hildebrandt, Melhem Solh, Ronald Sobecks, Jacob M. Rowe, Shahrukh K. Hashmi, Zhen-Huan Hu, Jack W. Hsu, Yoshihiro Inamoto, Aaron T. Gerds, Harry C. Schouten, Mohamed A. Kharfan-Dabaja, Muthalagu Ramanathan, Matt Kalaycio, Jane L. Liesveld, Jan Cerny, David S. Snyder, Zachariah DeFilipp, Taiga Nishihori, Mark B. Juckett, Celalettin Ustun, Andrew Daly, Ashish Bajel, Mahmoud Aljurf, Bipin N. Savani, Rammurti T. Kamble, Mehdi Hamadani, Kirk R. Schultz, Mark R. Litzow, Mary Lynn Savoie, Ran Reshef, Jean A. Yared, Siddhartha Ganguly, Robert Peter Gale, Sachiko Seo, Edwin P. Alyea
Publikováno v:
Biol Blood Marrow Transplant
Biology of Blood and Marrow Transplantation, 26(3), 472-479. Elsevier Science
Biology of Blood and Marrow Transplantation, 26(3), 472-479. Elsevier Science
It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML).
Autor:
Mohamed A. Kharfan-Dabaja, Leo F. Verdonck, Tania Jain, Gregory A. Hale, Navneet S. Majhail, Baldeep Wirk, Caitrin Fretham, Mahmoud Aljurf, Hemant S. Murthy, Kwang Woo Ahn, Ulrike Bacher, Wael Saber, Bart L. Scott, Jean Yves-Cahn, Daniel J. Weisdorf, Nosha Farhadfar, Richard F. Olsson, Michael R. Grunwald, Amer Beitinjaneh, Bipin N. Savani, Christopher Bredeson, Mark R. Litzow, Shatha Farhan, Jean A. Yared, Sachiko Seo, Jeff Szer, Gerhard C. Hildebrandt, Jan Cerny, David A. Rizzieri, Mitchell Sabloff, Ran Reshef, Vaibhav Agrawal, Robert Peter Gale, Ryotaro Nakamura, Saurabh Chhabra, Attaphol Pawarode, Taiga Nishihori, David I. Marks, Uday R. Popat, Siddhartha Ganguly, Miguel Angel Diaz, Betul Oran, Matt Kalaycio, Edward A. Copelan, Asad Bashey, Hillard M. Lazarus, Jane L. Liesveld, Shahrukh K. Hashmi, Marjolein van der Poel, Sunita Nathan
Publikováno v:
Transplantation and Cellular Therapy, 27(11). Elsevier
Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the 2 most commonly used RIC regimens,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d6a14a48b561685478be682fe7d726
https://cris.maastrichtuniversity.nl/en/publications/3af6c0ea-79ff-47be-b3cc-a5349bd89b26
https://cris.maastrichtuniversity.nl/en/publications/3af6c0ea-79ff-47be-b3cc-a5349bd89b26
Autor:
Hillard M. Lazarus, Minoo Battiwalla, Jean A. Yared, Baldeep Wirk, Robert Peter Gale, Ibrahim Ahmed, Marcelo C. Pasquini, Sachiko Seo, Bipin N. Savani, Leona Holmberg, Richard T. Maziarz, Gerhard C. Hildebrandt, Richard F. Olsson, Nelli Bejanyan, Shahinaz M. Gadalla, Mingwei Fei, Kehinde Adekola, Mahmoud Aljurf, Oscar B Lahoud, Jeffrey Auletta, Seth J. Rotz, Vaibhav Agrawal, Claudio G. Brunstein, Jan Cerny, Soyoung Kim, Shin Mineishi, Vikram Mathews, Harry C. Schouten, Siddhartha Ganguly, Cesar O. Freytes, Miguel-Angel Perales, Joseph S. Bubalo, Peiman Hematti, Maxim Norkin, Ran Reshef, Marcos de Lima, Taiga Nishihori, Stefan O. Ciurea, John Rogosheske, Heather Landau, Lynette Chee, Shahrukh K. Hashmi
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol 25, iss 3
Biology of Blood and Marrow Transplantation, 25(3), 480-487. Elsevier Science
Biology of Blood and Marrow Transplantation, 25(3), 480-487. Elsevier Science
Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index
Autor:
Angela Desmond, Muthalagu Ramanathan, Jayde Bednarik, Rajneesh Nath, Neeraj Saini, Imran Puthawala, Glen D. Raffel, Jan Cerny, Zheng Zhou, Lindsey Shanahan, Vanessa Fiorini Furtado, Patricia M. Miron, Bruce A. Woda
Publikováno v:
American Journal of Hematology. 94:209-215
An intensive "5 + 1" regimen, which included bolus high dose cytarabine (HiDAC) at 3 g/m2 once daily over 3 hours on days 1-5 and high dose mitoxantrone (HDM) 80 mg/m2 on day 2, was evaluated in 101 consecutively treated newly diagnosed acute myeloid